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OBJECTIVE — We investigated whether supplementation of the active form of vitamin D
(calcitriol)inrecent-onsettype1diabetescanprotect-cellfunctionevaluatedbyC-peptideand
improve glycemic control assessed by A1C and insulin requirement.
RESEARCH DESIGN AND METHODS — Thirty-four subjects (aged 11–35 years,
median18years)withrecent-onsettype1diabetesandhighbasalC-peptide0.25nmol/lwere
randomized in a double-blind trial to 0.25 g/day calcitriol or placebo and followed-up for 2
years.
RESULTS — At6,12,and24monthsfollow-up,A1Candinsulinrequirementinthecalcitriol
group did not differ from the placebo group. C-peptide dropped signiﬁcantly (P  0.001) but
similarly in both groups, with no signiﬁcant differences at each time point.
CONCLUSIONS — Atthedosesused,calcitriolisineffectiveinprotecting-cellfunctionin
subjects (including children) with recent-onset type 1 diabetes and high C-peptide at diagnosis.
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V
itamin D deﬁciency has been asso-
ciated with type 1 diabetes (1). Sev-
eral studies suggest that vitamin D
supplementation in early childhood de-
creases the risk of developing type 1 dia-
betes (2,3). The aim of this pilot trial was
to investigate whether the supplementa-
tion of the active form of vitamin D (cal-
citriol) in subjects with recent-onset type
1diabetesisabletoprotectresidual-cell
function(C-peptide)andtoimprovemet-
abolic control.
RESEARCH DESIGN AND
METHODS— Patients with recent-
onset type 1 diabetes (17 female and 17
male subjects; aged 11–35 years, median
18 years) were studied. Criteria for in-
clusion were 1) diagnosis according to
the American Diabetes Association, 2)
age at presentation between 11 and 35
years, 3) duration of clinical disease
(since the beginning of insulin therapy)
12 weeks, and 4) baseline C-peptide
0.25 nmol/l.
A double-blind trial was designed
with patients randomized to 0.25 g/
daily calcitriol (the active form of vitamin
D,1.25-dihydroxyvitaminD3)orplacebo
and followed-up for 2 years. The study
was approved by ethical committees of
the participating institutions, with in-
formed consent signed by patients or par-
ents, where appropriate.
Guidelines for insulin therapy
The same protocol for insulin treatment as
in previous IMmunotherapy of DIABetes
(IMDIAB) trials (4) was applied.
Investigations and follow-up
Fasting C-peptide, A1C, and 25(OH) vi-
tamin D levels were evaluated up to 24
months. Stimulated C-peptide meal test
was performed at baseline and at 12
months using a Boost High-Protein stan-
dardized liquid meal, with blood samples
drawn at baseline and 30, 60, and 120
min. C-peptide was evaluated by chemi-
luminescence on an ADVIA Centaur ana-
lyzer and serum 25-hydroxyvitamin D
(25OHD) by radioimmunoassay (Dia-
sorin), detecting both forms of 25OHD.
Statistical power and analysis
The number of patients to be included in
the trial was calculated from setting a dif-
ference in basal C-peptide of 0.12 nmol/l
at 2 years after diagnosis between the cal-
citriol and placebo groups. Setting 
(probability of type 1 error) equal to 0.05
and  (probability of type 2 error) equal
to 80%, the required sample size was 26
patients for a two-sided test. To ensure an
appropriate sample size, 34 patients were
recruited to allow for drop outs. Multiple
comparison by ANOVA was used to
compare treatment groups across time
points with Bonferroni correction where
appropriate.
RESULTS— Twenty-seven subjects
(79.4%)completedthetrial,15inthecal-
citriolgroupand12intheplacebogroup.
Overall, there were 16 of 34 subjects
(47%) with a signiﬁcant vitamin D deﬁ-
ciency(bloodlevels20ng/ml),whereas
at 24 months 25OHD levels were slightly
increased in the calcitriol group (3.9%)
and reduced in the placebo group
(8.0%).
At 6, 12, and 24 months, A1C, C-
peptide, and insulin requirement values
did not differ between calcitriol and pla-
cebo groups. The area under the curve of
C-peptide response (AUC0–120 min) was
not signiﬁcantly different in the calcitriol
versus placebo group at baseline (calcit-
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min; placebo group: 72.5  37.7; P 

0.658) or after 12 months (calcitriol
group: 49.7  30.4 nmol/l 	 120 min;
placebo group: 56.2  39.7; P 
 0.845).
Fasting C-peptide dropped signiﬁ-
cantly in both groups during follow-up
(P  0.001). Mean rate of decline in fast-
ingC-peptideafter12monthswas17.7%
in the calcitriol group and 28.4% in the
placebo group. After 24 months, the rate
ofC-peptidedeclinewas44.4%inthecal-
citriol group and 42.5% in the placebo
group.At12months,theAUC0–120 minof
C-peptide dropped signiﬁcantly in both
the calcitriol (P  0.03) and control (P 
0.04) groups. No differences were ob-
served in the mean C-peptide response
after mixed meal at different time points
betweenthetwogroups.VitaminDstatus
didnotinﬂuenceresidual-cellfunction.
Likewise, vitamin D deﬁciency at diagno-
sis was not associated with lower residual
-cell function at 24 months (C-peptide
in patients with 25OHD levels 20
ng/ml: 0.19  0.09 nmol/l vs. 0.22 
0.16 nmol/l in patients with 25OHD
levels 20 ng/ml; P 
 0.408). Calcium
and phosphate levels remained within
normal limits throughout the follow-up,
and no adverse events were reported in
any patient.
CONCLUSIONS — In the ﬁrst pilot
trial with calcitriol, Walter et al. (5) re-
ported no differences in fasting C-
peptide, AUC C-peptide, and peak
C-peptide after a mixed meal between
treated and placebo groups at 9 and 18
months. A1C and insulin requirement
were also similar between the groups. In
the aforementioned study, no threshold
of C-peptide level at study entry was de-
ﬁned. We designed a trial in which pa-
tients were younger at diagnosis,
including also children, and should have
had basal C-peptide levels at entry 0.25
nmol/lsothatapossibleeffectofcalcitriol
on disease progression could have been
detected. We have shown that calcitriol
does not affect residual -cell function in
such patients, even those of younger age.
Similar to the German trial describing a
mean C-peptide decrease of 40% at 18
months, in our study, decline of C-
peptideafter24monthswas44.4%inthe
calcitriol group and 42.5% in the placebo
group. These ﬁndings substantially con-
ﬁrm the data from combined studies col-
lected by the TrialNet Research Group on
decline of C-peptide (6).
In the study by Walter et al. (5), se-
rum concentrations of the active form of
vitamin D 1.25(OH)2D3 were deter-
mined only in 13 patients in the safety
phase, at baseline, and after 9 months of
treatment, and they increased signiﬁ-
cantly(24.6vs.30.3pg/ml;P0.02).On
the contrary, we found that plasma levels
of 25OHD were only modestly modiﬁed
by the oral supplementation of calcitriol.
In view of the association of supple-
mentation of vitamin D early in life with a
riskreductionoftype1diabetes(2,3,7),it
is likely that the protective effects of vita-
min D may be beneﬁcial in modulating
the initiation of the autoimmune process.
However, supplementation after disease
onset does not induce any beneﬁcial
effect.
In conclusion, the results of this trial
indicate that, at the doses used, calcitriol
is ineffective in preserving residual -cell
function.
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